Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Olaparib · 1 trial · 1 indication
To determine DCR by assessing complete/partial response or stable disease, as per RECIST 1.1 in patients with mMGMT TNBC treated with Temozolomide ± Olaparib.
| Arm | Type | Description |
|---|---|---|
| Temozolomide Arm | EXPERIMENTAL | Temozolomide: 50 mg/m2 daily in cycles of 21 days |
| Temozolomide+Olaparib Arm | EXPERIMENTAL | Temozolomide 75 mg/m2 day 1 to day 7 with Olaparib 200 mg BID, oral, day 1 to day 7 in cycles of 21 days |
| Name | Type | Description |
|---|---|---|
| Temozolomide | DRUG | Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms. |
| Olaparib | DRUG | Olaparib will be administered orally twice daily in treatment arm 2. |
Inclusion Criteria: * Female or male patients with triple negative breast cancer confirmed by pathology of the primary tumour or metastatic biopsy sample. Estrogen receptor (ER) and progesterone receptor (PgR) must be ≤2 Allred score by Immunohistochemistry (IHC); human epidermal growth factor rece...
Olaparib is being studied for the treatment of triple negative breast cancer (TNBC). It is an investigational small molecule in Phase 2 clinical development for this indication. The drug is being evaluated in a clinical trial in Canada.
Olaparib targets PARP, a class of enzymes involved in DNA repair. By inhibiting PARP, the drug is intended to exploit vulnerabilities in cancer cells. It is being studied in biomarker-selected patients with triple negative breast cancer.
Olaparib is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company's ticker symbol is ALBT. The drug is currently in Phase 2 clinical development for triple negative breast cancer.
Olaparib is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a Phase 2 trial for triple negative breast cancer.
Olaparib is being evaluated in clinical trial NCT05128734, titled "Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)". This Phase 2 trial is not yet recruiting and plans to enroll 40 participants in Canada.
Olaparib is also known by its generic name and is sometimes referred to as a PARP inhibitor. No alternative brand names have been established for this investigational drug in the context of this development program.